Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets
Immunovant, Inc. (NASDAQ: IMVT) stock is closing out the week in focus after the company completed a major equity raise designed to bolster funding for its autoimmune pipeline—while its controlling shareholder, Roivant Sciences, stepped in as the largest buyer. As of the most recent market close ahead of Sunday, December 14, 2025, IMVT shares were around $26.42, up about 6.6%…